Advances of Epigenetic Editing Gjaltema, Rutger a F; Rots, Marianne G

Total Page:16

File Type:pdf, Size:1020Kb

Advances of Epigenetic Editing Gjaltema, Rutger a F; Rots, Marianne G University of Groningen Advances of epigenetic editing Gjaltema, Rutger A F; Rots, Marianne G Published in: Current Opinion in Chemical Biology DOI: 10.1016/j.cbpa.2020.04.020 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2020 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Gjaltema, R. A. F., & Rots, M. G. (2020). Advances of epigenetic editing. Current Opinion in Chemical Biology, 57, 75-81. https://doi.org/10.1016/j.cbpa.2020.04.020 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 Available online at www.sciencedirect.com ScienceDirect Advances of epigenetic editing Rutger A. F. Gjaltema1 and Marianne G. Rots2 Abstract questions at the endogenous locus level, as well to Epigenetic editing refers to the locus-specific targeting of function as preclinical tools to engineer gene transcrip- epigenetic enzymes to rewrite the local epigenetic landscape tion. The foundation of epigenetic editing is formed by of an endogenous genomic site, often with the aim of tran- the ability to generate fusion proteins of epigenetic scriptional reprogramming. Implementing clustered regularly enzymes or their catalytic domains (CDs)with pro- interspaced short palindromic repeat–dCas9 greatly acceler- grammable DNA-binding platforms such as the clus- ated the advancement of epigenetic editing, yielding preclinical tered regularly interspaced short palindromic repeat therapeutic successes using a variety of epigenetic enzymes. (CRISPR) Cas9 to target these to an endogenous locus ,CRISPR/dCas9 Here, were review the current applications of of choice (Figure 1)[2,3]. The enzymatic fusion protein these epigenetic editing tools in mammalians and shed light on then dictates the initial deposited modification while biochemical improvements that facilitate versatile applications. subsequent cross-talk within the local chromatin envi- ronment likely influences epigenetic and transcriptional Addresses output. In this review, we discuss recent advances of 1 Otto-Warburg-Laboratory, Max Planck Institute for Molecular Ge- epigenetic editing in mammals based on the CRISPRe netics, Berlin, Germany 2 Department of Pathology and Medical Biology, University of Gronin- dCas9 platform, with emphasis on the latest chemical gen, University Medical Center Groningen, Groningen, the Netherlands and biotechnological developments to control temporal and on-target activity. Corresponding author: Rots, Marianne G ([email protected]) Epigenetic editing of DNA methylation Current Opinion in Chemical Biology 2020, 57:75–81 DNA methylation (5mC) at CpG islands in promoter This reviews comes from a themed issue on Chemical Genetics and regions is associated with transcriptional repressive Epigenetics states. Targeting DNA methyltransferases (DNMTs) to Edited by Akane Kawamura and Arasu Ganesan those regions would allow target gene repression through inducing de novo 5mC. Indeed, the full length or For a complete overview see the Issue and the Editorial the CD of human or mouse DNMT3A in fusion with dCas9 (dCas9eDNMT3A and dCas9eDNMT3ACD, https://doi.org/10.1016/j.cbpa.2020.04.020 respectively) introduced de novo 5mC up to w60% at 1367-5931/© 2020 The Author(s). Published by Elsevier Ltd. This is an targeted regions (mostly promoters) which was followed open access article under the CC BY license (http://creativecommons. by inhibition of transcription [4]. In a direct comparison org/licenses/by/4.0/). between full-length dCas9eDNMT3A and the dCas9e DNMT3ACD, the latter displayed more efficient 5mC Keywords activity, whereas dCas9eDNMT3A induced less off- CRISPR/dCas, Epigenome editing, Targeted DNA methylation, Targe- target 5mC [5]. ted histone modifications, Expression reprogramming. For enhanced targeted 5mC, various approaches have Introduction been tested: first, fusions of DNMT3ACD and DNMT3L, a stimulator of DNMT3A catalytic activity Epigenetic modifications of DNA and histones are [6] (dCas9eDNMT3A3 L), could induce w5-fold known for their multifaceted contributions to tran- more 5mC deposition at various target loci than those scriptional regulation. As these modifications are faith- of dCas9eDNMT3ACD [7], although not nearing a fully propagated throughout DNA replication [1], they fully methylated state of target regions. Another report are considered central players in cellular memory of confirmed these observations [8]. As a second transcriptional states. Many efforts in the last decade approach, full-length DNMT3A was applied to an have generated a vast understanding of individual adaptation of the SunTag system [5] to enable the epigenetic modifications and their contribution to recruitment of multiple copies of scFv-DNMT3ACD transcriptional regulation. However, standing questions fusion proteins (Figure 2B) [9]. Despite multimer remain regarding how and which modifications recruitment, de novo 5mC was lower than that of a contribute to a certain transcriptional output. Epige- dCas9eDNMT3ACD fusion. Alternatively, increasing netic editing offers powerful tools to dissect these the nuclear trafficking of dCas9eDNMT3ACD www.sciencedirect.com Current Opinion in Chemical Biology 2020, 57:75–81 76 Chemical Genetics and Epigenetics Figure 1 Principle of epigenetic editing. Epigenetic editing with the CRISPR/dCas9 platform involves targeting an effector domain (ED) fused to dCas9 (dCas9-ED) (a) Upon sgRNA-mediated recruitment to a target location (e.g. promoter) the dCas9-ED is able to rewrite the local epigenetic state such as histone tails or 5mC (depicted as lollipops) and thereby modify transcriptional activity (b). CRISPR, clustered regularly interspaced short palindromic repeat. through cloning a nucleoplasmin nuclear localization hydroxymethylcytosine and further intermediates. To signal C-terminally of DNMT3ACD improved targeted initiate targeted demethylation of 5mC, dCas9 fusions 5mC from w40 to w60% [10], suggesting that con- with TET1CD were targeted to methylated regions ventional dCas9eDNMT3ACD fusions experience [10,13e17] but with a varied degree of demethylation lower nuclear translocation. In addition, simultaneous efficiencies, likely depending on genetic and chromatin targeting of dCas9 fusions with DNMT3A, DNMT3L, context, as well as on delivery efficacy of the dCas9 and the Kru¨ppel associated box (KRAB) repressor has tools. Even despite partial DNA demethylation of been successfully applied to induce repressive tran- target regions, transcriptional reactivation of the scriptional memory [11] and effective epigenetic targeted genes was rather weak, likely caused by reprogramming at CCCTC-binding factor (CTCF) remaining repressive microenvironment (e.g. deacety- binding sites [8]. In addition to mammalian DNMTs, lated histones, H3K9me2) [15]. In addition to cultured the prokaryotic CpG methyltransferase (M.SssI) has cells, targeted DNA demethylation has also been been explored for targeted DNA methylation. Target- applied in preclinical mouse models. For example, ing a humanized M.SssI derivative (dCas9eMQ1) targeted demethylation of CGG-repeats within the introduced high levels of de novo 5mC (up to w70%) fragile X mental retardation 1 (FMR1) promoter that was widely spread alongside the target region [12]. through lentiviral expression of dCas9-TET1CD in However, due to extensive off-target 5mC, further post-mitotic neurons obtained from patient-derived modifications to M.SssI are required for it to be induced pluripotent stem cells (iPSCs) restored exploited for targeted DNA methylation ( ‘Precision FMR1 expression and neuronal function in culture and epigenetic editing’). was even maintained following engrafting into mouse brains [19]. In another report, in vivo lentiviral delivery As various disease-related genes are repressed by DNA of dCas9eTET3CD in a kidney fibrosis mouse model methylation, targeted demethylation would offer resulted in targeted promoter demethylation and sub- unique therapeutic possibilities. Active DNA deme- sequent reactivation of two antifibrotic genes, which thylation is initiated by ten-eleven translocation diox- attenuated kidney fibrosis and restored kidney function ygenases (TETs) that oxidize 5mC to 5- [20]. Current Opinion in Chemical Biology 2020, 57:75–81 www.sciencedirect.com Transcriptional reprogramming by epigenome engineering Gjaltema and Rots 77 Figure 2 Enhanced CRISPR–dCas9–based epigenetic editors. (a) Second-generation CRISPR systems contain RNA aptamers (MS2 or PP7) linked to the sgRNA handle, which recruit their corresponding aptamer coat protein (MCP or PCP, respectively) fused to (epigenetic) effector domains (EDs). (b) The SunTag system consists of a dCas9 fusion with GCN4 peptide repeats that enable the recruitment of multiple copies of
Recommended publications
  • Editing DNA Methylation in Mammalian Embryos
    International Journal of Molecular Sciences Review Editing DNA Methylation in Mammalian Embryos Taiga Yamazaki 1,* , Yu Hatano 2, Ryoya Taniguchi 2, Noritada Kobayashi 1 and Kazuo Yamagata 2,* 1 Division of Biomedical Research, Kitasato University Medical Center, Kitasato University, 6-100 Arai, Kitamoto, Saitama 364-8501, Japan; [email protected] 2 Faculty of Biology-Oriented Science and Technology, KINDAI University, 930 Nishimitani, Kinokawa, Wakayama 649-6493, Japan; [email protected] (Y.H.); [email protected] (R.T.) * Correspondence: [email protected] (T.Y.); [email protected] (K.Y.); Tel.:+81-48-593-1212 (T.Y.), +81-736-77-3888 (K.Y.) Received: 11 December 2019; Accepted: 16 January 2020; Published: 18 January 2020 Abstract: DNA methylation in mammals is essential for numerous biological functions, such as ensuring chromosomal stability, genomic imprinting, and X-chromosome inactivation through transcriptional regulation. Gene knockout of DNA methyltransferases and demethylation enzymes has made significant contributions to analyzing the functions of DNA methylation in development. By applying epigenome editing, it is now possible to manipulate DNA methylation in specific genomic regions and to understand the functions of these modifications. In this review, we first describe recent DNA methylation editing technology. We then focused on changes in DNA methylation status during mammalian gametogenesis and preimplantation development, and have discussed the implications of applying this technology to early embryos. Keywords: DNA methylation; epigenome editing; preimplantation embryo; germ cell; centromere; pericentromere 1. Introduction Cytosine methylation is a process in which methyl groups are added to the cytosine of CpG dinucleotides, forming 5-methylcytosine (5mC).
    [Show full text]
  • Spatiotemporal Control of CRISPR/Cas9 Gene Editing
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN Spatiotemporal control of CRISPR/Cas9 gene editing Chenya Zhuo1, Jiabin Zhang1, Jung-Hwan Lee2, Ju Jiao3, Du Cheng4, Li Liu5, Hae-Won Kim2,YuTao1 and Mingqiang Li 1,6 The clustered regularly interspaced short palindromic repeats (CRISPR)/associated protein 9 (CRISPR/Cas9) gene editing technology, as a revolutionary breakthrough in genetic engineering, offers a promising platform to improve the treatment of various genetic and infectious diseases because of its simple design and powerful ability to edit different loci simultaneously. However, failure to conduct precise gene editing in specific tissues or cells within a certain time may result in undesirable consequences, such as serious off-target effects, representing a critical challenge for the clinical translation of the technology. Recently, some emerging strategies using genetic regulation, chemical and physical strategies to regulate the activity of CRISPR/Cas9 have shown promising results in the improvement of spatiotemporal controllability. Herein, in this review, we first summarize the latest progress of these advanced strategies involving cell-specific promoters, small-molecule activation and inhibition, bioresponsive delivery carriers, and optical/thermal/ultrasonic/magnetic activation. Next, we highlight the advantages and disadvantages of various strategies and discuss their obstacles and limitations in clinical translation. Finally, we propose viewpoints on directions that can be explored to
    [Show full text]
  • Strategies for Precision Modulation of Gene Expression by Epigenome Editing: an Overview Benjamin I
    Laufer and Singh Epigenetics & Chromatin (2015) 8:34 DOI 10.1186/s13072-015-0023-7 REVIEW Open Access Strategies for precision modulation of gene expression by epigenome editing: an overview Benjamin I. Laufer* and Shiva M. Singh Abstract Genome editing technology has evolved rather quickly and become accessible to most researchers. It has resulted in far reaching implications and a number of novel designer systems including epigenome editing. Epigenome editing utilizes a combination of nuclease-null genome editing systems and effector domains to modulate gene expression. In particular, Zinc Finger, Transcription-Activator-Like Effector, and CRISPR/Cas9 have emerged as modular systems that can be modified to allow for precision manipulation of epigenetic marks without altering underlying DNA sequence. This review contains a comprehensive catalog of effector domains that can be used with components of genome editing systems to achieve epigenome editing. Ultimately, the evidence-based design of epigenome editing offers a novel improvement to the limited attenuation strategies. There is much potential for editing and/or correcting gene expression in somatic cells toward a new era of functional genomics and personalized medicine. Keywords: Regulation of gene expression, Functional genomics, Stem cells, dCas9, CRISPR/Cas9, Zinc Finger, Transcription-Activator-Like Effector (TALE), Synthetic biology Background editing systems rely on two components, a DNA-bind- The modulation of gene expression can be achieved by ing element, and nuclease, to modify the targeted DNA a variety of biotechnologies such as RNA interference, sequence. Genome editing can be used to study protein non-precision drugs, and artificial transcription factors function by altering coding sequence or achieve tran- (ATFs).
    [Show full text]
  • Stem Cells, Genome Editing and the Path to Translational Medicine
    Stem Cells, Genome Editing, and the Path to Translational Medicine The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Soldner, Frank and Rudolf Jaenisch. "Stem Cells, Genome Editing, and the Path to Translational Medicine." Cell 175, 3 (October 2018): P615-632 © 2018 Elsevier Inc As Published http://dx.doi.org/10.1016/j.cell.2018.09.010 Publisher Elsevier BV Version Author's final manuscript Citable link https://hdl.handle.net/1721.1/125973 Terms of Use Creative Commons Attribution-NonCommercial-NoDerivs License Detailed Terms http://creativecommons.org/licenses/by-nc-nd/4.0/ HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Cell. Author Manuscript Author manuscript; Manuscript Author available in PMC 2019 October 18. Published in final edited form as: Cell. 2018 October 18; 175(3): 615–632. doi:10.1016/j.cell.2018.09.010. Stem cells, genome editing and the path to translational medicine Frank Soldner1 and Rudolf Jaenisch1,2,3 1The Whitehead Institute, 455 Main Street, Cambridge, MA 02142, USA 2Department of Biology, Massachusetts Institute of Technology, 31 Ames Street, Cambridge, MA 02139, USA Summary The derivation of human embryonic stem cells (hESCs) and the stunning discovery that somatic cells can be reprogrammed into human induced pluripotent stem cells (hiPSCs) holds the promise to revolutionize biomedical research and regenerative medicine. In this review, we focus on disorders of the central nervous system and explore how advances in human pluripotent stem cells (hPSCs) coincide with evolutions in genome engineering and genomic technologies to provide realistic opportunities to tackle some of the most devastating complex disorders.
    [Show full text]
  • Challenges, New Technologies and Their Use in Plants
    International Journal of Molecular Sciences Review Chromatin Manipulation and Editing: Challenges, New Technologies and Their Use in Plants Kateryna Fal 1,† , Denisa Tomkova 2,†, Gilles Vachon 1 , Marie-Edith Chabouté 2, Alexandre Berr 2,* and Cristel C. Carles 1,* 1 Laboratoire de Physiologie Cellulaire et Végétale, Université Grenoble Alpes, CNRS, CEA, INRAE, IRIG-LPCV, 38000 Grenoble, France; [email protected] (K.F.); [email protected] (G.V.) 2 Institut de Biologie Moléculaire des Plantes du CNRS, Université de Strasbourg, 12 rue du Général Zimmer, 67084 Strasbourg CEDEX, France; [email protected] (D.T.); [email protected] (M.-E.C.) * Correspondence: [email protected] (A.B.); [email protected] (C.C.C.) † These authors contributed equally to this work. Abstract: An ongoing challenge in functional epigenomics is to develop tools for precise manipulation of epigenetic marks. These tools would allow moving from correlation-based to causal-based findings, a necessary step to reach conclusions on mechanistic principles. In this review, we describe and discuss the advantages and limits of tools and technologies developed to impact epigenetic marks, and which could be employed to study their direct effect on nuclear and chromatin structure, on transcription, and their further genuine role in plant cell fate and development. On one hand, epigenome-wide approaches include drug inhibitors for chromatin modifiers or readers, nanobodies against histone marks or lines expressing modified histones or mutant chromatin effectors. On the other hand, locus-specific approaches consist in targeting precise regions on the chromatin, with engineered proteins able to modify epigenetic marks.
    [Show full text]
  • Concurrent Genome and Epigenome Editing by CRISPR-Mediated Sequence Replacement Jes Alexander1,2, Gregory M
    Alexander et al. BMC Biology (2019) 17:90 https://doi.org/10.1186/s12915-019-0711-z METHODOLOGY ARTICLE Open Access Concurrent genome and epigenome editing by CRISPR-mediated sequence replacement Jes Alexander1,2, Gregory M. Findlay1, Martin Kircher1 and Jay Shendure1,3,4,5* Abstract Background: Recent advances in genome editing have facilitated the direct manipulation of not only the genome, but also the epigenome. Genome editing is typically performed by introducing a single CRISPR/Cas9-mediated double- strand break (DSB), followed by non-homologous end joining (NHEJ)- or homology-directed repair-mediated repair. Epigenome editing, and in particular methylation of CpG dinucleotides, can be performed using catalytically inactive Cas9 (dCas9) fused to a methyltransferase domain. However, for investigations of the role of methylation in gene silencing, studies based on dCas9-methyltransferase have limited resolution and are potentially confounded by the effects of binding of the fusion protein. As an alternative strategy for epigenome editing, we tested CRISPR/Cas9 dual cutting of the genome in the presence of in vitro methylated exogenous DNA, with the aim of driving replacement of the DNA sequence intervening the dual cuts via NHEJ. Results: In a proof of concept at the HPRT1 promoter, successful replacement events with heavily methylated alleles of a CpG island resulted in functional silencing of the HPRT1 gene. Although still limited in efficiency, our study demonstrates concurrent epigenome and genome editing in a single event. Conclusions: This study opens the door to investigations of the functional consequences of methylation patterns at single CpG dinucleotide resolution. Our results furthermore support the conclusion that promoter methylation is sufficient to functionally silence gene expression.
    [Show full text]
  • Novel Epigenetic Techniques Provided by the CRISPR/Cas9
    Hindawi Stem Cells International Volume 2018, Article ID 7834175, 12 pages https://doi.org/10.1155/2018/7834175 Review Article Novel Epigenetic Techniques Provided by the CRISPR/ Cas9 System 1,2 1,2 1,2 1,3,2 Nina Xie , Yafang Zhou, Qiying Sun , and Beisha Tang 1Department of Geriatric Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China 2National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, Hunan 410078, China 3Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China Correspondence should be addressed to Beisha Tang; [email protected] Received 4 November 2017; Revised 4 February 2018; Accepted 27 March 2018; Published 8 July 2018 Academic Editor: Changwon Park Copyright © 2018 Nina Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Epigenetics classically refers to the inheritable changes of hereditary information without perturbing DNA sequences. Understanding mechanisms of how epigenetic factors contribute to inheritable phenotype changes and cell identity will pave the way for us to understand diverse biological processes. In recent years, the emergence of CRISPR/Cas9 technology has provided us with new routes to the epigenetic field. In this review, novel epigenetic techniques utilizing the CRISPR/Cas9 system are the main contents to be discussed, including epigenome editing, temporal and spatial control of epigenetic effectors, noncoding RNA manipulation, chromatin in vivo imaging, and epigenetic element screening. 1. Introduction RNA, researchers could target Cas9 nuclease to almost any locus in the genome precisely.
    [Show full text]
  • Chemical and Light Inducible Epigenome Editing
    International Journal of Molecular Sciences Review Chemical and Light Inducible Epigenome Editing Weiye Zhao , Yufan Wang and Fu-Sen Liang * Department of Chemistry, Case Western Reserve University 2080 Adelbert Road, Cleveland, OH 44106, USA; [email protected] (W.Z.); [email protected] (Y.W.) * Correspondence: [email protected] Received: 22 December 2019; Accepted: 30 January 2020; Published: 3 February 2020 Abstract: The epigenome defines the unique gene expression patterns and resulting cellular behaviors in different cell types. Epigenome dysregulation has been directly linked to various human diseases. Epigenome editing enabling genome locus-specific targeting of epigenome modifiers to directly alter specific local epigenome modifications offers a revolutionary tool for mechanistic studies in epigenome regulation as well as the development of novel epigenome therapies. Inducible and reversible epigenome editing provides unique temporal control critical for understanding the dynamics and kinetics of epigenome regulation. This review summarizes the progress in the development of spatiotemporal-specific tools using small molecules or light as inducers to achieve the conditional control of epigenome editing and their applications in epigenetic research. Keywords: epigenome; epigenome modifications; chemically induced proximity; light control 1. Introduction Chemical modification patterns on histone tails and DNA collectively constitute the epigenome that dictates unique gene expression patterns and resulting phenotypes in each distinct cell type [1–3]. The alterations of the epigenome due to the dysregulation of epigenome pathways and mutations of epigenome regulators contributes to pathogenesis of various human diseases including many developmental diseases and cancers [4–19]. Several epigenetic regulatory mechanisms including DNA methylations, histone tail posttranslational modifications (PTMs), ATP-dependent chromatin remodeling and non-coding RNAs have been shown to play key roles in governing gene activities [6,7,15,20–29].
    [Show full text]
  • Chimerization Enables Gene Synthesis and Lentiviral Delivery of Customizable TALE-Based Effectors
    International Journal of Molecular Sciences Article Chimerization Enables Gene Synthesis and Lentiviral Delivery of Customizable TALE-Based Effectors 1,2 1,2, 1,2,3 1,2, Yongxing Fang , Wladislaw Stroukov y, Toni Cathomen and Claudio Mussolino * 1 Institute for Transfusion Medicine and Gene Therapy, Medical Center—University of Freiburg, 79106 Freiburg, Germany; [email protected] (Y.F.); [email protected] (W.S.); [email protected] (T.C.) 2 Center for Chronic Immunodeficiency (CCI), Medical Center—University of Freiburg, 79106 Freiburg, Germany 3 Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany * Correspondence: [email protected]; Tel.: +49-761-270-77738 Current address: Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, y King’s College London, SE1 9RT London, UK. Received: 20 December 2019; Accepted: 23 January 2020; Published: 25 January 2020 Abstract: Designer effectors based on the DNA binding domain (DBD) of Xanthomonas transcription activator-like effectors (TALEs) are powerful sequence-specific tools with an excellent reputation for their specificity in editing the genome, transcriptome, and more recently the epigenome in multiple cellular systems. However, the repetitive structure of the TALE arrays composing the DBD impedes their generation as gene synthesis product and prevents the delivery of TALE-based genes using lentiviral vectors (LVs), a widely used system for human gene therapy. To overcome these limitations, we aimed at chimerizing the DNA sequence encoding for the TALE-DBDs by introducing sufficient diversity to facilitate both their gene synthesis and enable their lentiviral delivery. To this end, we replaced three out of 17 Xanthomonas TALE repeats with TALE-like units from the bacterium Burkholderia rhizoxinica.
    [Show full text]
  • What Is CRISPR/Cas9? Page 5
    Your Guide to Understanding CRISPR 1 Contact [email protected] | (888) 611-6883 20161130 TABLE OF CONTENTS Introduction Page 3 A Brief History of CRISPR Page 3 Gene Editing Before CRISPR Page 4 What is CRISPR/Cas9? Page 5 CRISPR Applications Page 7 CRISPR Guides Page 9 Developments in Synthetic sgRNA Page 12 Alternatives to S. pyogenes Cas9 Page 13 Gene Editing is Just the Beginning Page 14 2 Contact [email protected] | (888) 611-6883 20161130 INTRODUCTION CRISPR is igniting a revolution. A relatively recent discovery in the timeline of biotechnology, CRISPR is quickly becoming a standard and flexible laboratory tool, and it is well on its way to permeating a large variety of applications. Researchers are deploying CRISPR across a wide range of life science disciplines, from agriculture and medicine to biofuels and industrial fermentation. Read on for a crash course in everything you need to know if you’re just getting your first taste of CRISPR. A BRIEF HISTORY OF CRISPR The foundational discoveries that led to CRISPR/Cas9 technology can be traced back to 1993, when the genomic regions known as CRISPR loci were first identified. In 2007, after years of studying CRISPR genetic motifs, researchers came to the conclusion that CRISPR’s function is related to microbial cellular immunity. Throughout the next 5 years, several research groups worked to elucidate the underlying molecular mechanisms behind CRISPR in Prokaryotes. CRISPR works as a form of Prokaryotic immunity that identifies, targets, and eliminates bacteriophage and foreign DNA. By 2012, researchers realized that CRISPR could be adapted for engineering the genomes of microbes, plants, animal, and other varieties of cells.
    [Show full text]
  • S41467-017-00644-Y.Pdf
    ARTICLE DOI: 10.1038/s41467-017-00644-y OPEN Rapid and reversible epigenome editing by endogenous chromatin regulators Simon M.G. Braun1, Jacob G. Kirkland 1, Emma J. Chory 1,2, Dylan Husmann1, Joseph P. Calarco1 & Gerald R. Crabtree1,3 Understanding the causal link between epigenetic marks and gene regulation remains a central question in chromatin biology. To edit the epigenome we developed the FIRE-Cas9 system for rapid and reversible recruitment of endogenous chromatin regulators to specific genomic loci. We enhanced the dCas9–MS2 anchor for genome targeting with Fkbp/Frb dimerizing fusion proteins to allow chemical-induced proximity of a desired chromatin reg- ulator. We find that mSWI/SNF (BAF) complex recruitment is sufficient to oppose Polycomb within minutes, leading to activation of bivalent gene transcription in mouse embryonic stem cells. Furthermore, Hp1/Suv39h1 heterochromatin complex recruitment to active promoters deposits H3K9me3 domains, resulting in gene silencing that can be reversed upon washout of the chemical dimerizer. This inducible recruitment strategy provides precise kinetic infor- mation to model epigenetic memory and plasticity. It is broadly applicable to mechanistic studies of chromatin in mammalian cells and is particularly suited to the analysis of endo- genous multi-subunit chromatin regulator complexes. 1 Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, CA 94305, USA. 2 Department of Chemical Engineering, Stanford University, Stanford, CA 94305, USA. 3 Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Simon M.G. Braun, and Jacob G. Kirkland contributed equally to this work. Correspondence and requests for materials should be addressed to G.R.C.
    [Show full text]
  • Epigenome Editing to the Rescue
    neWs and VieWs Epigenome editing to the rescue Epigenetic dysregulation of gene expression is a major contributor to many human dis- eases. Targeted alteration of the epigenome became possible with the advent of customiz- able DNA binding domains, and the approach was quickly tested in animal models1 and in clinical trials. In recent years, the develop- ment of easily programmable genome editors based on CRISPR–Cas9 has renewed inter- est in epigenome editing technologies and their therapeutic applications2. Now, a new Reproduced with permission from Liu, X.S. et al. Cell 172, 979–992.e6 (2018) study in Cell3 has demonstrated the power of using specific editing of epigenomic marks to reverse the effects of a genetic mutation. repeat methylation was so closely linked to the neurons derived from the implanted cells Epigenome editing makes use of the same removal of heterochromatin marks and the still expressed FMR1. Interestingly, at least customizable DNA binders (zinc finger pro- appearance of active chromatin marks at the in vitro, maintaining expression of FMR1 did teins, TALEs or CRISPR–Cas9) that are used promoter,” says Charles Gersbach, professor of not require sustained dCas9–Tet1 activity. for genome editing or for general transcrip- biomedical engineering at Duke University in When the authors expressed a Cas9 inhibi- tional activation or repression. But instead of Durham, North Carolina. tor, FMR1 expression was unchanged for at being fused to a nuclease or to a transcrip- Off-target demethylation events were rare. least two weeks. tional activator or repressor, the DNA binder Although ChIP-seq detected >1,000 sites that Further characterization of the therapeu- carries an enzyme that puts in place or erases were at least transiently bound by the dem- tic effects of dCas9–Tet1 was complicated by a specific epigenetic mark2.
    [Show full text]